Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.32 Insider Own4.64% Shs Outstand64.04M Perf Week9.46%
Market Cap105.48M Forward P/E- EPS next Y-0.33 Insider Trans0.00% Shs Float62.09M Perf Month52.83%
Income-20.76M PEG- EPS next Q-0.09 Inst Own10.64% Short Float0.24% Perf Quarter92.81%
Sales0.00M P/S- EPS this Y10.36% Inst Trans- Short Ratio0.54 Perf Half Y62.06%
Book/sh0.40 P/B4.07 EPS next Y-2.23% ROA-50.89% Short Interest0.15M Perf Year187.80%
Cash/sh0.46 P/C3.52 EPS next 5Y- ROE-60.62% 52W Range0.45 - 1.70 Perf YTD92.13%
Dividend Est.- P/FCF- EPS past 5Y-47.09% ROI-80.15% 52W High-4.71% Beta1.04
Dividend TTM- Quick Ratio5.29 Sales past 5Y-25.00% Gross Margin- 52W Low260.00% ATR (14)0.14
Dividend Ex-Date- Current Ratio5.29 EPS Y/Y TTM15.15% Oper. Margin0.00% RSI (14)65.87 Volatility12.19% 11.12%
Employees22 Debt/Eq0.01 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price4.31
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q29.93% Payout- Rel Volume0.88 Prev Close1.52
Sales Surprise- EPS Surprise24.51% Sales Q/Q- EarningsNov 15 BMO Avg Volume275.08K Price1.62
SMA2029.19% SMA5051.62% SMA20077.82% Trades Volume241,689 Change6.58%
Feb-21-24 07:27AM
Feb-15-24 07:27AM
Jan-24-24 07:27AM
Jan-09-24 07:27AM
Dec-05-23 07:27AM
05:30AM Loading…
Nov-16-23 05:30AM
Nov-01-23 07:27AM
Oct-20-23 05:00PM
Oct-13-23 09:24AM
Oct-11-23 01:05PM
Oct-10-23 06:00AM
Sep-27-23 09:34AM
Sep-26-23 07:27AM
Sep-19-23 07:27AM
Aug-09-23 07:27AM
07:27AM Loading…
Aug-08-23 07:27AM
Jun-29-23 10:19AM
Jun-27-23 07:27AM
May-09-23 07:15AM
Mar-29-23 07:27AM
Mar-07-23 07:27AM
Jan-17-23 02:59PM
Dec-12-22 07:27AM
Nov-14-22 05:00PM
Nov-07-22 07:27AM
Oct-25-22 06:30AM
Oct-03-22 07:27AM
Sep-28-22 08:20AM
Sep-27-22 09:05AM
07:29AM Loading…
Aug-03-22 07:29AM
Jul-12-22 06:14AM
Jun-29-22 10:07AM
Jun-27-22 10:07AM
Jun-09-22 04:05PM
May-27-22 01:00PM
May-24-22 07:00AM
May-19-22 07:27AM
May-17-22 07:27AM
May-02-22 02:42PM
Mar-24-22 07:27AM
Mar-22-22 07:27AM
Mar-15-22 07:27AM
Mar-01-22 07:27AM
Feb-02-22 06:30AM
Jan-19-22 07:27AM
Nov-05-21 09:18AM
Nov-04-21 08:52AM
Nov-03-21 08:36AM
Nov-02-21 04:04PM
Oct-25-21 07:27AM
Oct-18-21 07:27AM
Sep-16-21 07:27AM
Sep-10-21 04:33PM
Sep-07-21 07:27AM
Aug-24-21 07:27AM
Aug-19-21 06:52AM
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.